The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI
about
Aspartame: A Safety Evaluation Based on Current Use Levels, Regulations, and Toxicological and Epidemiological StudiesPET/CT imaging of c-Myc transgenic mice identifies the genotoxic N-nitroso-diethylamine as carcinogen in a short-term cancer bioassayA data-based assessment of alternative strategies for identification of potential human cancer hazards.Detection of the onset of ischemia and carcinogenesis by hypoxia-inducible transcription factor-based in vivo bioluminescence imagingSpontaneous tumor incidence in rasH2 mice: review of internal data and published literature.Oncogenicity evaluation of resveratrol in p53(+/-) (p53 knockout) mice.Biomarkers of cancer risk and therapeutic benefit: new technologies, new opportunities, and some challenges.Creation and preliminary characterization of a Tp53 knockout rat.Animal models of malignant mesothelioma.Evaluation of dichloroacetic acid for carcinogenicity in genetically modified Tg.AC hemizygous and p53 haploinsufficient mice.Science, politics, and health in the brave new world of pharmaceutical carcinogenic risk assessment: technical progress or cycle of regulatory capture?Benzene-induced hematopoietic neoplasms including myeloid leukemia in Trp53-deficient C57BL/6 and C3H/He mice.An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.Best practices for clinical pathology testing in carcinogenicity studies.Establishing a laboratory animal model from a transgenic animal: RasH2 mice as a model for carcinogenicity studies in regulatory science.Insights into wild-type and mutant p53 functions provided by genetically engineered mice.Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.Twenty-six-week oral carcinogenicity study of 3-monochloropropane-1,2-diol in CB6F1-rasH2 transgenic mice.Regulatory Forum commentary: alternative mouse models for future cancer risk assessment.Hematopoietic proliferative lesions in the spleen of rasH2 transgenic mice treated with MNU.Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention.The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.N-Methyl-N-Nitrosourea (MNU): A positive control chemical for p53+/- mouse carcinogenicity studies.Evaluation of the carcinogenic potential of clofibrate in the p53+/- mouse.Studies evaluating the utility of N-methyl-N-nitrosourea as a positive control in carcinogenicity studies in the p53+/- mouse.Lung Tumor Induction by 26-week Dermal Application of 1,2-Dichloroethane in CB6F1-Tg rasH2 Mice.Progression process and safety assessment adaptation of endometrial lesions in ENU-induced 2-stage uterine carcinogenicity in a Tg-rasH2 mouse model.A one-year neonatal mouse carcinogenesis study of quinacrine dihydrochloride.Comparative dermal toxicity of dicyclohexylcarbodiimide and diisopropylcarbodiimide in rodents.Tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in an ultra-short-term skin carcinogenesis bioassay using rasH2 mice.Toxicology in the drug discovery and development process.
P2860
Q23901998-7815BFCF-F257-4692-994D-FB590033D7C1Q27309893-C0D93116-4241-4AEA-80F6-14B3232EB462Q33495954-13519367-AF51-4D24-BECF-545C11F3B267Q34079232-953A8CCB-F03D-48E5-8B8D-BDD3F4B85E16Q34157088-285D170E-C1E5-4069-A906-4F66B5CC206AQ35758133-92DF6CFA-8AE7-4C64-AB6D-C5AC3A8E0C51Q35812523-FFE4740B-766B-4692-8DF4-6513C3534401Q36486063-8A728774-559C-473A-B1E5-09303966EFD5Q36571864-7C4C42DD-CF83-4B27-83C8-4D6510534982Q37089734-A1C315F8-C258-449F-AEDA-ECC7E6D254E0Q37187425-5E33A418-E793-4B5A-A729-4157D73344D2Q37256614-D58C2509-7F8C-45BC-943C-FF6F87D3C155Q37628343-271370B7-D6CB-419F-BEE3-D1501EEE88D3Q37633279-2323DC51-DEF3-4699-BDA5-67F2B4F24974Q37836198-15A2349C-7335-4472-9453-790EB28E21E6Q37965371-EEE709C4-BD57-40CD-A9F6-E533DE201955Q38177769-75EC5E91-81BC-4235-8BAD-404453DC6703Q38208275-81B33625-3C47-4E5D-A3F6-D20F93A5132FQ38415892-C75CAFE7-A1FA-4A4C-92CA-B6F111AABB23Q39363493-0875BF25-DB49-49FB-9DE7-D4AAD3C4DEBDQ42872518-630FFBDA-77BA-4A19-A717-CC57399118FDQ43119645-3E7ED7F7-A32D-46FD-A9F5-6A09A134E8E4Q46322348-D1A203EB-9A87-43B6-A6D7-11B53526AD5CQ46338587-4B195230-8C1E-4120-8285-9A5196873964Q46781515-970BFE55-EDE0-437D-9E6E-FB9154E5F876Q46781535-7C109F40-496E-4ADD-A232-1A046068B980Q47789678-60F39D0C-789F-4C3C-BA8B-641A0EDB5A65Q50421948-74C70464-E9F4-45A9-B8EC-CD9C288D12D8Q51811785-01C56CAF-20CD-4B03-9C9B-0ACF8256658CQ53207707-CF35A2E8-112A-4F47-8E87-818C37E23432Q53255024-B307AE03-D782-4269-8FC8-6AB7C12E845AQ53347876-DD6AD2FF-8BF6-41F6-9579-F0FCD5E0E96C
P2860
The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The utility of genetically mod ...... ty Testing Committee ILSI HESI
@ast
The utility of genetically mod ...... ty Testing Committee ILSI HESI
@en
The utility of genetically mod ...... ty Testing Committee ILSI HESI
@nl
type
label
The utility of genetically mod ...... ty Testing Committee ILSI HESI
@ast
The utility of genetically mod ...... ty Testing Committee ILSI HESI
@en
The utility of genetically mod ...... ty Testing Committee ILSI HESI
@nl
prefLabel
The utility of genetically mod ...... ty Testing Committee ILSI HESI
@ast
The utility of genetically mod ...... ty Testing Committee ILSI HESI
@en
The utility of genetically mod ...... ty Testing Committee ILSI HESI
@nl
P2093
P356
P1476
The utility of genetically mod ...... ty Testing Committee ILSI HESI
@en
P2093
Abigail Jacobs
Bruce McCullough
Douglas Keller
Frank D Sistare
Gerald Long
James MacDonald
Jan Willem van der Laan
Jay Goodman
John E French
P304
P356
10.1093/TOXSCI/KFH037
P407
P577
2004-02-01T00:00:00Z